Study of Samalizumab in Patients With Advanced Cancer

Exclusion Criteria

• •1. Participant had a symptomatic brain metastasis.
• •2. Participant had active gastrointestinal bleeding as evidenced by either hematemesis or melena.
• •3. Participant had acute gastrointestinal ulcers.
• •4. Participant had a history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.
• •5. Participant with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration.
• •6. Participant had an active infection requiring therapy.
• •7. Participant's serum was positive for the presence of hepatitis B surface antigen, antibodies to hepatitis C virus, or antibodies to human immunodeficiency virus 1/2.
• •8. Participant had significant cardiovascular impairment (history of New York Heart Association Functional Classification system Class III or IV) or a history of myocardial infarction or unstable angina within the past 6 months prior to study drug treatment.
• •9. The participant's most recent test values within 14 days before the date of entry met the following standards:
• •* Bone marrow function: neutrophil count ≤1500/millimeter (mm)\^3, hemoglobin ≤9.0 grams/deciliter, platelet count ≤100,000/mm\^3.
• •* Liver function: total bilirubin ≥1.5 x the upper limit of normal (ULN) based on the standard value of each institution, aspartate aminotransferase and alanine aminotransferase ≥2.5 x ULN based on the reference laboratory.
• •* Renal function: serum creatinine ≥1.5 x ULN based on the reference laboratory.
• •10. Participant had ongoing immune-stimulated adverse events from other immunotherapies (for example, pneumonitis, thyroiditis, or hepatitis) or a history of pneumonitis.
• •11. Participant had received chemotherapy, targeted therapy, and/or immunotherapy within the 28 days prior to first dose of study drug, or within a Washout Period for the chemotherapy, targeted therapy, and/or immunotherapy of 5 half-lives, whichever occurred first.
• •12. Participant had toxicities from previous immunotherapy that had not resolved to Grade 1.